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Cefepime MIC Breakpoint Resettlement in Gram-Negative Bacteria
Cefepime has recently drawn much attention, due mostly to
a meta-analysis reported by Yahav et al. (3). They observed
higher all-cause mortality for cefepime than for other beta-
lactam antibiotics (risk ratio, 1.26; 95% confidence interval
[CI], 1.08 to 1.49) and described neurotoxic adverse effects and
inadequate in vivo antimicrobial efficacy as plausible reasons
for increased mortality.
Bhat et al. (1) observed increased mortality among
cefepime-treated patients with bacteremia caused by gram-
negative organisms when the cefepime MIC was 8 g/ml
(54.8%; 17 of 31 died) than when the MIC was 8 g/ml
(24.1%; 35 of 145 died). Based on pharmacodynamic and clin-
ical grounds, they suggested that the current breakpoints (ac-
cording to which organisms are considered susceptible if the
MIC is 8 g/ml by Clinical and Laboratory Standards Insti-
tute standards) for cefepime be lowered in countries where
cefepime dosages of 1 to 2 g every 12 h is the licensed therapy
for serious infections.
However, we suppose that subgroup analysis excluding
Pseudomonas aeruginosa and Acinetobacter spp. should reveal
consistent results with statistical evidence to generalize their
contention for other gram-negative organisms, because the
MICs for P. aeruginosa and Acinetobacter spp. have been re-
vealed to be much higher than those for other gram-negative
organisms. Bhat et al. presented details on 204 bloodstream
isolates from individual patients (the clinical outcomes for only
176 patients were analyzed because 21 patients were dis-
charged within 28 days and 7 patients had two episodes of
bacteremia), and P. aeruginosa and Acinetobacter spp. ac-
counted for 79.4% (27 of 34) of the isolates for which the MICs
were 8 g/ml while they constituted only 15.9% (27 of 170)
of those for which the MICs were 8 g/ml. We could not
identify the exact proportions of these two pathogens among
isolates from nonsurvivors for which MICs were 8 g/ml.
However, Bhat et al. observed a high odds ratio (OR) for
mortality among P. aeruginosa bacteremic patients through a
subgroup analysis that compared outcomes associated with
MICs of 8 g/ml (mortality, 59.1%; 13 of 22 patients died)
and those associated with MICs of 4 g/ml (mortality,
20.8%; 5 of 24 patients died), and when a reconstituted pop-
ulation excluding P. aeruginosa was analyzed on the basis of
MICs of 8 g/ml versus MICs of 4 g/ml, the analysis did
not reveal statistical significance (4 of 9 patients [44.8%] with
isolates for which MICs were 8 g/ml died, and 30 of 121
[24.8%] with isolates for which MICs were 8 g/ml died;
OR  2.4; 95% CI, 0.6 to 9.6). It seems quite reasonable to
reconsider the current breakpoint MIC of cefepime (8 g/ml)
for P. aeruginosa. However, additional verification is required
to resettle the cefepime MIC breakpoint for gram-negative
pathogens other than P. aeruginosa and Acinetobacter spp. We
believe that this verification may be accomplished through a
subgroup analysis excluding P. aeruginosa and Acinetobacter
spp. and providing statistical evidence.
In 2006, the probability of target attainment (PTA) for the
conventional dose of cefepime (2 g every 12 h) against com-
mon intensive care unit (ICU) pathogens in ICU patients was
estimated (2). According to the results of the study, higher
doses of cefepime (4 g/day) are required to achieve the
required PTA expectation value for P. aeruginosa, and even a
higher dose (6 g/day) failed to achieve the bactericidal target
for Acinetobacter baumannii, unlike that for other pathogens.
Like various MIC distributions, we suppose that MIC break-
point resettlement requires verifications for different patho-
gens.
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Authors’ Reply
Chin and Seo question whether breakpoint MICs for
cefepime should be reassessed for organisms other than P.
aeruginosa. In particular, they ask whether a subgroup analysis
excluding P. aeruginosa or Acinetobacter spp. allows us to gen-
eralize a change in breakpoints for all gram-negative bacilli.
Breakpoints should be reassessed when new mechanisms of
antibiotic resistance are detected at some time after the break-
points were originally determined (5). With respect to gram-
negative organisms other than P. aeruginosa, a number of
mechanisms of antibiotic resistance have been discovered
which elevate the MICs of cefepime. Foremost among these
are a variety of beta-lactamases which can hydrolyze cefepime,
thereby compromising its activity (2). The MIC for at least
10% of extended-spectrum beta-lactamase (ESBL)-producing
klebsiellae, for example, is 8 g/ml (3), which is precisely the
MIC of interest in this discussion.
Reevaluation of breakpoints should be via evaluation of clinical
data and pharmacokinetic/pharmacodynamic (PK/PD) data (5).
Our clinical data showed that 56.3% of patients with a blood-
stream infection due to a gram-negative organism for which the
cefepime MIC was 8 g/ml died, compared to 24.1% of those
infected with an organism for which the cefepime MIC was 8
g/ml (1). Our original purpose was to study gram-negative bacilli
in toto rather than subgroups. However, the subgroup of P.
aeruginosa dominates this discussion because P. aeruginosa is the
most common organism for which the cefepime MIC is 8 g/ml.
Formal statistical analysis of organisms other than P. aeruginosa is
impossible because of small numbers. With respect to the Entero-
bacteriaceae, only six patients had a bloodstream infection with an
organism for which the MIC was 8 g/ml or higher. Of those
infected with an organism for which the cefepime MIC was 8
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g/ml, two survived and one died. (The patient who died had a
polymicrobial infection with Enterobacter cloacae, for which the
cefepime MIC was 8 g/ml, and P. aeruginosa, for which the
cefepime MIC was 1 g/ml).
Evaluation of PK/PD data has suggested that a cefepime dos-
ing regimen of 1 to 2 g every 12 h risks a suboptimal probability
of attaining important PK/PD targets (1). These targets are not
specific for P. aeruginosa but are shared by the Enterobacteriaceae
(1). Chin and Seo cite the study by Roos et al. (4) in their letter.
The analysis by Roos et al. (4) in fact showed that the probability
of target attainment for any gram-negative organism for which
the cefepime MIC is 8 g/ml is less than 30% when 1 to 2 g of
cefepime is administered every 12 h. This finding supports the
concept that it is inappropriate to interpret a cefepime MIC of 8
g/ml to indicate susceptibility for any organism.
Certainly, it would be optimal for a large amount of clinical
data to be available to support breakpoint revisions. In a case
where clinical data are sparse, if the PK/PD data are compel-
ling for the inadequacy of a dosing regimen for a certain MIC,
it is appropriate either to change breakpoints based on the
PK/PD analysis or to screen for the presence of mechanisms of
resistance that would increase the MIC (5). We do not believe
that screening for mechanisms of resistance solves the issue in
this circumstance. We observed 11 patients infected with
ESBL-producing Enterobacteriaceae. Mortality data were avail-
able for 10 of these patients, and 50% died. Importantly, 8 of
these 10 patients had infections caused by isolates that would
currently be reported as susceptible on the basis of the
cefepime MIC (MIC  8 g/ml). The majority of ESBL-pro-
ducing organisms in our study were species of Enterobacter, a
genus for which ESBL detection methods are not widely avail-
able. Thus, if diagnostic microbiology laboratories cannot ag-
gressively test for ESBL production, then these cases of hidden
resistance will go undetected by the microbiologist and the
clinician, with the potential for untoward consequences. For
this reason alone, we feel that cefepime breakpoints for En-
terobacteriaceae should be lowered, removing the risk of organ-
isms with hidden ESBLs resulting in MICs that PK/PD analy-
ses suggest would not be adequately achieved by commonly
used cefepime doses. Breakpoint change for cefepime and the
Enterobacteriaceae would remove this risk.
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